Management of the Elderly Inflammatory Bowel Disease Patient

Petr Hruz\textsuperscript{a} Pascal Juillerat\textsuperscript{b} Gerd-Achim Kullak-Ublick\textsuperscript{c} Alain M. Schoepfer\textsuperscript{d} Gerassimos J. Mantzaris\textsuperscript{e} Gerhard Rogler\textsuperscript{f}

\textsuperscript{a}Department of Gastroenterology and Hepatology, Clarunis Basel, Basel, Switzerland; \textsuperscript{b}Department of Gastroenterology and Hepatology, University Clinic for Visceral Surgery and Medicine, University Hospital of Bern, Bern, Switzerland; \textsuperscript{c}Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; \textsuperscript{d}Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; \textsuperscript{e}Department of Gastroenterology, “Evangelismos-Ophthalmiatreion Athinon-Polycliniki” Hospitals, Athens, Greece; \textsuperscript{f}Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

Keywords
Crohn’s disease · Ulcerative colitis · Elderly · Management

Abstract
Inflammatory bowel disease (IBD) is increasingly diagnosed among elderly persons (older than 60 years). Epidemiological studies show that late-onset IBD is characterized by predominance of colonic disease, milder disease course, and less frequent occurrence of extraintestinal manifestations. However, due to comorbidities, polypharmacy and reduced resistance to severe disease course elderly patients have an increased risk of mortality. Drug treatment generally follows the same algorithms as in the younger IBD patients. This is challenging for the treating physician as this population is usually underrepresented in clinical trials and treatment outcomes as well as safety data on the elderly population are scarce. Choice of drugs should consider risk of infections, skin cancer, lymphoma, and metabolic as well as cardiovascular side effects. Considering comorbidities, surgical interventions such as colectomy with ileo-anal pouch anastomosis for refractory ulcerative colitis can be performed safely provided that the anal sphincter function is adequately maintained. Special attention should be given in this age group to general health issues, including nutrition, vaccination, bone, muscle, and mental health as well as colorectal and skin cancer screening. © 2020 S. Karger AG, Basel

Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are both chronic inflammatory conditions of the gut related to a combination of genetic and environmental factors that impact on normal host – microbe interactions \cite{1}. More and more importance is attributed to age-related immunosenescence which is associated with a relative systemic immunodeficiency compared with younger people, with declines in functionality of both innate and adaptive immunity\cite{2,3}. Immune disturbances of the luminal mucosal immune system with ageing might result in an inability to mount protective immune responses to exposure to new antigens \cite{4}. These antigens are arising from commensal microorganisms, dietary products, and occasional pathogens, but these factors explain only a small
fraction of disease risk. Another factor may be endothelial dysfunction that is considered an initial step in the pathogenesis of atherosclerosis in the general population. In inflammatory bowel disease (IBD), the inflammatory process leads to functional and structural changes in the vascular endothelium with an increase of leukocyte adhesion and leukocyte diapedesis and an increased vascular smooth muscle tone and procoagulant activity is observed [5, 6]. In younger IBD patients, genetic factors are probably of greater importance than in older patients where cumulative exposure to environmental factors (exposome) may have a more prominent role to drive disease development. So just 7% of CD subjects over the age of 60 had a family history versus 16% of patients with disease onset before 16 years of age [7]. The term “exposome” was proposed to reflect a life-course of environmental influences beginning in utero and proceeding right through childhood to adulthood [8, 9]. Several factors such as diet, food additives (dietary emulsifiers), nanoparticles, air and water pollution, exposure to smoking, drugs (e.g., antibiotics and nonsteroidal anti-inflammatory drugs), infections, hypoxia, and others have been identified as environmental contributors in this concept [10].

The Role of the Microbiota in Older IBD Patients

Intestinal dysbiosis is associated with several chronic conditions, including inflammatory diseases. IBD patients characteristically show a reduced biodiversity and altered composition of the intestinal microbiota with quantitatively increased abundance in bacteria which include Enterobacteriaceae, Pasteurellaceae, Veillonellaceae, and Fusobacteriaceae and decreased abundance in Erysipelotrichales, Bacteroidales, and Clostridiales which correlates strongly with disease status [11, 12]. The microbiota of older people display greater inter-individual variation than that of younger adults [13]. Analysis of microbiota of elderly subjects with different residence locations (community, day-hospital, rehabilitation, or in long-term residential care) indicated that gut microbiota correlate to diet and health condition upon ageing [14]. Interestingly, the individual microbiota of people in long-stay care was significantly less diverse than that of community dwellers and loss of community-associated microbiota correlated with increased frailty. One of the potential factors where the microbiome is altered as a consequence of exposure to an environmental factor is use of antibiotics [15, 16]. Microbiome comparison between CD patients with and without antibiotic exposure indicates that antibiotic use amplifies the microbial dysbiosis associated with CD [11]. Modulating intestinal microbial composition therefore may represent a promising strategy for treatment of patients with IBD. Fecal microbiota transplantation and probiotics have been explored as promising candidates to reestablish microbial balance in IBD [17]. These microbiota-based therapies have demonstrated the ability to reduce both the dysbiotic environment and production of inflammatory mediators, thus inducing remission, especially in a part of UC patients [18–20]. Whether the changes of the microbiota seen in the elderly play a specific role for IBD disease course remains to be elucidated. Systematic analyses in cohorts of older patients and comparisons with younger cohorts have not been performed. As it has been postulated that the composition of the microbiota in the elderly may contribute to changes in the intestinal mucosal innate immune system and immune reactions this analysis would indeed be important.

Epidemiology

Epidemiological data are often reported together for both forms of IBD, UC, and CD with most of IBD patients being diagnosed at young age. Several studies have shown a bimodal age distribution with a peak incidence in the second to fourth decade and a second smaller peak in incidence in the sixth to eighth decade [21, 22]. Due to worldwide rising incidence of IBD and as a consequence of the ageing population an increase in the incidence and prevalence rate of IBD in the elderly is not surprising [23]. Factors such as urbanization, improved disease awareness, or improved diagnostics have been attributed to increase the number of elderly individuals living with IBD. Estimations for the incidence rates in UC in the elderly are ranging between 3 and 17 per 100,000 and in CD between 3 and 6 per 100,000 [7, 24, 25]. A recent nationwide population-based study from Sweden reported an incidence rate of 35 per 100,000 person years for IBD patients >60 years or older with a clearly higher rate for UC compared to CD [26]. Several population-based studies suggest that late-onset IBD has a milder clinical course with less frequent use of immunomodulators as well as biologics, a lower rate of extraintestinal manifestations, and similar surgery rates when compared with younger IBD patients [7, 24–26]. However, especially correlating the use of drug treatments with the clinical course may be misleading as use of different drug classes may be influenced by comorbidities and polypharmacy in the elderly population and some drug classes may be avoided by the prescribing physicians for safety reasons.
As shown in the population-based study from Sweden elderly patients used fewer biologics and immunomodulators but had a higher use of systemic corticosteroids compared with pediatric and adult-onset IBD [26].

**Clinical Presentation**

The clinical presentation of patients with CD and UC differs between older and younger patients. Older-onset of CD is more frequently associated with isolated colonic inflammation and perianal fistulas and less small bowel and upper gastrointestinal disease [7, 25]. Inflammatory phenotype is more often observed in elderly CD patients than stricturing or penetrating disease. Elderly UC patients tend to have less isolated proctitis but more left-sided and extensive colitis, and the disease location in elderly UC patients tends to remain stable with only a small fraction of patients showing disease extension at follow-up [7]. A considerable delay in diagnosis of up to 6 years in the elderly compared to 2 years in younger adults has been observed [27]. Overall elderly IBD patients present with more subtle clinical symptoms. Elderly-onset CD subjects report less abdominal pain, systemic symptoms, and diarrhea, while subjects with a diagnosis of UC in older age report less abdominal pain and rectal bleeding [28]. In the differential diagnosis, the evaluation aims to exclude primarily malignancies (cancer and lymphoma) and infectious causes. But several other conditions of gastrointestinal inflammation can occur in the elderly that include diverticulitis, ischemic colitis, microscopic colitis, drug-induced colitis (e.g., nonsteroidal anti-inflammatory drugs), or in case of a personal history of radiation therapy radiation-induced colitis (proctitis) and all these conditions should be excluded [29]. It is important to assess the personal and medical history for preexisting conditions such as cardiovascular diseases, diabetes mellitus, malignancies, functional and cognitive impairments, smoking history, and renal dysfunction which are prevalent comorbidities in elderly and which is crucial for correct assessment of the clinical condition and subsequently initiation of treatment.

**Treatment**

**General Management and Treatment of Elderly IBD Patients**

Management of elderly IBD patients has been insufficiently studied since older adults are underrepresented in clinical trials and no specific treatment algorithms have been developed for this age group. In recent years in many clinical trials, patients older than 65 were systematically excluded. Therefore, currently drug treatment in the elderly follows principles that are established for younger IBD patients. Benefits of the chosen drug treatment should outweigh potential side effects and should consider specific safety issues. This is highly relevant as in a recent Swiss IBD Cohort study addressing safety issues a positive correlation between the number of concomitantly administered IBD drugs and the occurrence of side effects requiring drug cessation was observed [30]. Also in the elderly population, additional factors have to be considered as cardiovascular diseases, hypertension, diabetes mellitus, malignancies, functional and cognitive impairments, smoking history, and renal dysfunction are more prevalent [31]. Physicians should be at greater awareness that these patients may be treated already with different medications as polypharmacy increases the risk of drug-drug interactions and may trigger or worsen concomitant diseases [31]. Age-dependent changes in liver and renal function and age-related body composition (increase of body fat, decrease of lean muscle mass, hypoproteinemia) may impair the pharmacokinetics of medications and have to be considered while prescribing additional therapies in these patients. Specific attention has to be given also to infections in IBD patients on immunosuppressive therapy as they tend to occur more often due to age-related alterations in natural barriers and immunesenescence and are prone to a more serious clinical course [32].

In summary, treatment strategies in elderly IBD patients based on the location and severity of inflammation should implement the following goals: to induce and maintain remission to prevent disease-related complications, to avoid adverse events, and to improve quality of life. In the following sections, the commonly used IBD drug classes are discussed and information about side effects, drug-drug interactions, and specific recommendations is provided in Table 1.

**5-Aminosalicylates**

Oral and topical 5-aminosalicylates (5-ASA) are highly effective as induction and maintenance treatment for UC but less effective in CD [33–36]. Interestingly, a recent analysis indicates that mesalazine was the most frequent prescribed drug treatment for the elderly IBD patients and 80% of CD and 84% of UC patients have been treated with mesalazine within 10 years of diagnosis [7, 37]. The high frequency of mesalazine
### Table 1. Common side effects and drug-drug interactions for therapies used in elderly IBD patients

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Substance(s)</th>
<th>Side effects</th>
<th>Drug-drug interactions</th>
<th>Precautions and specific recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aminosalicylates</strong></td>
<td>Mesoalazine (5-ASA)</td>
<td>- Rare (&lt;0.1%) headache, dizziness, abdominal pain, bloating, diarrhea, nausea, vomiting, arthralgia, myalgia, skin rash</td>
<td>- In combination with thiopurines 5-ASA increases the anticoagulant activity of warfarin</td>
<td>Monitoring of laboratory parameters (blood count and renal function)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Very rare (&lt;0.01%): nephrotoxicity, leukopenia, hepatitis</td>
<td>- Concomitant use of CYP3A4 inhibitors increase concentrations and effect of steroids</td>
<td>- Pronounced adverse events in elderly patients; limit prescription to short applications (&lt;3 months)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- In combination with NSAIDs increased risk for peptic ulcer</td>
<td>- Clinical and laboratory monitoring: blood pressure, diabetes, eyes, cosguilation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Steroids modulate the activity of anticoagulant drugs, reduce the effects of antidiabetic agents, increase the hypokalemic effects of diuretics</td>
<td>- Osteoporosis prevention and screening</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Anti-epileptic drugs (phensobarbital, phenytoin) reduce the efficacy of steroids</td>
<td>- Monitoring of laboratory parameters (blood count, liver function, lipase)</td>
</tr>
<tr>
<td><strong>Corticosteroids</strong></td>
<td>Prednisone</td>
<td>- General occurrence of metabolic and endocrine side effects including diabetes, hypertension, adrenal suppression, gynaecomastia</td>
<td>- Increased risk of myelotoxicity in combination with allopurinol</td>
<td>- Monitoring of laboratory parameters (blood count, liver function, lipase)</td>
</tr>
<tr>
<td></td>
<td>Budesonide*</td>
<td>- Increased risk for osteoporosis, impaired wound healing, myopathy, aseptic necrosis of bones, gastrointestinal bleeding or perforation, infections, glaucoma, depression, delirium, psychosis</td>
<td>- Increased risk of leukopenia in combination with 5-ASA</td>
<td>- TPMT activity or check drug level of metabolites</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Use not recommended in elderly patients</td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Contraindicated in cardiac history of malignancy, especially lymphoma</td>
<td>- Supplementation with folic acid 5 mg 24 h after methotrexate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Specific attention to liver disease</td>
<td>- Increased risk of myelotoxicity in combination with 5-ASA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Use with caution in patients with chronic hepatitis (hepatotoxicity) and renal insufficiency</td>
<td>- Avoid grape fruit juice</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
<td>- Regular monitoring for renal function, cyclosporine drug level</td>
</tr>
<tr>
<td><strong>Thiopurines</strong></td>
<td>Azathioprine 6-Mercaptopurine</td>
<td>- Nausea, vomiting (5–10%)</td>
<td>- Various drug-drug interactions due to alterations in plasma protein binding, renal clearance, and intestinal resorption</td>
<td>- Use not recommended in elderly patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Flu-like symptoms (2%)</td>
<td>- Increased methotrexate concentration in combination with 5-ASA, NSAIDs, antibiotics (penicillin, tetracyclines, sulfonylamides)</td>
<td>- Check for hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Leukopenia (&lt;10%), agranulocytosis (&lt;0.5%)</td>
<td>- Methotrexate decreases theophylline clearance, increases the effect of coumarin derivatives</td>
<td>- Avoid grape fruit juice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Pancreatitis (5–15%) hepatotoxicity (10%)</td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
<td>- Regular monitoring for renal function, cyclosporine drug level</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Skin rash (&lt;5%)</td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
<td>- Use not recommended in elderly patients</td>
</tr>
<tr>
<td><strong>Folate antagonist</strong></td>
<td>Methotrexate (indication for low-dose application)</td>
<td>- Abdominal discomfort, nausea, vomiting, diarrhea (&gt;10%), stomatitis (1–10%)</td>
<td>- Use not recommended in elderly patients</td>
<td>- Use not recommended in elderly patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Headache, fatigue (&lt;10%), dizziness (&lt;1%)</td>
<td>- Increased risk of myelotoxicity in combination with allopurinol</td>
<td>- Check for hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Hair loss (&lt;1%), skin rash (&lt;10%)</td>
<td>- Increased risk of leukopenia in combination with 5-ASA</td>
<td>- Avoid grape fruit juice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Increased liver enzymes (&gt;10%), chronic use with risk for liver cirrhosis</td>
<td>- Methotrexate decreases theophylline clearance, increases the effect of coumarin derivatives</td>
<td>- Regular monitoring for renal function, cyclosporine drug level</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Interstitial pneumonitis (1–10%)</td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
<td>- Use not recommended in elderly patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Myalgia, arthralgia (&lt;1%)</td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
<td>- Check for hypertension</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Anemia, leukopenia, thrombocytopenia (&lt;10%), agranulocytosis (&lt;0.01%)</td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
<td>- Avoid grape fruit juice</td>
</tr>
<tr>
<td><strong>Calcineurin inhibitor</strong></td>
<td>Cyclosporine</td>
<td>- Headache, migraine (15%), tremor (10–20%), paresthesia (&lt;10%)</td>
<td>- Drug interactions can occur with drugs that are substrates of CYP3A4 and P-glykoprotein</td>
<td>- Use not recommended in elderly patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Abdominal discomfort, nausea, vomiting, gingival hyperplasia (&gt;10%)</td>
<td>- Avoid concomitant use of drugs with nephrotoxic properties</td>
<td>- Avoid grape fruit juice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Renal insufficiency (10–50%), hypertension (15–40%), increase of liver enzymes (&lt;10%)</td>
<td>- Use not recommended in elderly patients</td>
<td>- Regular monitoring for renal function, cyclosporine drug level</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Leukopenia (5–10%), hyperlipidemia (&gt;10%)</td>
<td>- Use not recommended in elderly patients</td>
<td>- Use not recommended in elderly patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Hypertrichosis (&gt;10%), acne, rash (1–10%)</td>
<td>- Use not recommended in elderly patients</td>
<td>- Avoid grape fruit juice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Increased risk for infections</td>
<td>- Use not recommended in elderly patients</td>
<td>- Regular monitoring for renal function, cyclosporine drug level</td>
</tr>
<tr>
<td><strong>TNFα blockers</strong></td>
<td>Infliximab</td>
<td>- Headache, fatigue, dizziness, fever (1–10%)</td>
<td>- Concomitant use of immunomodulators may suppress the formation of antidrug antibodies</td>
<td>- Use not recommended in elderly patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Abdominal discomfort, nausea (1–10%)</td>
<td>- Screening before treatment</td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Increased risk of infections (1–10%), including opportunistic infections</td>
<td>- Contraindicated in cardiac insufficiency (NYHA III–IV)</td>
<td>- Contraindicated in cardiac insufficiency (NYHA III–IV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Infusion reactions, allergic reactions (5–10%)</td>
<td>- Use with caution in patients with chronic liver disease, neurological pathology, or history of malignancy, especially lymphoma</td>
<td>- Use with caution in patients with chronic liver disease, neurological pathology, or history of malignancy, especially lymphoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Skin rash (5–10%), various skin diseases (1–5%), TNFα blocker induced psoriasis (&lt;1%)</td>
<td>- Screening before treatment</td>
<td>- Contraindicated in cardiac insufficiency (NYHA III–IV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Lupus-like syndrome (&lt;1%), anaphylaxis (&lt;1%)</td>
<td>- Concomitant use of immunomodulators may suppress the formation of antidrug antibodies</td>
<td>- Use with caution in patients with chronic liver disease, neurological pathology, or history of malignancy, especially lymphoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- In general better side effect profile of subcutaneous application formulations</td>
<td>- Monitoring of laboratory parameters (blood count and liver enzymes)</td>
<td>- Contraindicated in cardiac insufficiency (NYHA III–IV)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Local irritation at injection site</td>
<td>- Concomitant use of immunomodulators may suppress the formation of antidrug antibodies</td>
<td>- Use with caution in patients with chronic liver disease, neurological pathology, or history of malignancy, especially lymphoma</td>
</tr>
</tbody>
</table>
use in older adults might be explained by its excellent tolerability and the limited number of alternatives, especially for mild to moderate disease course. In patients with ulcerative proctitis or left-sided colitis, a combination of oral and topical 5-ASA is more effective than either alone [38]. For better adherence rates, once-daily dosing is recommended as compliance is an important issue in the elderly. Problems with self-administration of topical agents especially with suppositories, enemas, and foam may limit usage in some elderly patients due to impaired mobility and incontinence [35, 39, 40].

5-ASA are generally considered safe and efficacious, the most common adverse reactions include nausea and vomiting, headache, abdominal pain, and rash [38]. Nephrotoxicity is a rare adverse event in patients on 5-ASA treatment and specific attention should be given to patients with underlying kidney disease. Renal function should be checked before and during therapy. Leukopenia can occur when 5-ASA agents are used in combination with thiopurines, due to an increase in 6-thioguanine levels, the active metabolite of azathioprine, and 6-mercaptopurine (6-MMP) [41, 42].

**Steroids**

As fast-acting drugs, corticosteroids are often used as induction agents in both UC and CD for rapid control of symptoms. A significant use of corticosteroids is reported in elderly IBD patients [7, 43, 44], and a recent analysis demonstrates that a proportion of 20–40% of IBD patients are treated with corticosteroids during the first 5 years following IBD diagnosis [26]. Therefore, metabolic (i.e., diabetes mellitus, dyslipidemia, weight gain, lipodystrophy) and cardiovascular (i.e., hypertension, cardiovascular events) adverse events have to be considered specifically in this patient group and repetitive or prolonged courses of corticosteroids should be avoided [45]. Prolonged use of steroid-based therapies may worsen different clinical conditions such as preexisting diabetes mellitus, hypertension, infections (e.g., pneumonia), eye lens cataract, or may cause mental state alterations [31, 46]. Attention has to be given also to corticosteroid-induced osteoporosis and the risk of bone fractures. In Swiss IBD patients, corticosteroids and age were the most relevant risk factors for decreased bone mineral density [47].

---

**Table 1 (continued)**

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Substance(s)</th>
<th>Side effects</th>
<th>Drug-drug interactions</th>
<th>Precautions and specific recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Integrin inhibitors</td>
<td>Vedolizumab</td>
<td>– Nasopharyngitis (10%) upper respiratory and intestinal infections (1–10%)</td>
<td>Pharmacokinetic studies with thiopurines or methotrexate do not indicate relevant changes in pharmacokinetics of vedolizumab</td>
<td>– Screening before treatment*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Headache (10%), arthralgia (&gt;10%)</td>
<td></td>
<td>– Monitoring of laboratory parameters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Abdominal discomfort, nausea (1–10%)</td>
<td></td>
<td>– No signal for PML</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Allergic infusion reactions (&lt;1%), fever (1–10%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-IL-12/23 Ab</td>
<td>Ustekinumab</td>
<td>– Headache, fatigue, dizziness (5–10%)</td>
<td>Attention to combination therapies with other immunosuppressive drugs due to potentiation of immunosuppression and risk for severe infections</td>
<td>– Screening before treatment*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Nasopharyngitis (5–10%), lower respiratory tract infections (&lt;1%), cellulitis (&lt;1%)</td>
<td></td>
<td>– Monitoring of laboratory parameters</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Abdominal discomfort, vomiting, nausea, diarrhea (&lt;10%)</td>
<td></td>
<td>– Rare observation: reversible PRES</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Arthralgia (5–10%), urticaria (&lt;1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Local irritation at injection site (1–10%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small molecule</td>
<td>Tofacitinib</td>
<td>– Headache, fatigue (&lt;10%)</td>
<td>Drug interactions can occur with drugs that are substrates of CYP3A4 and CYP2C19</td>
<td>– Laboratory monitoring (blood count, lipid status, creatinine kinase)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Upper/lower respiratory tract and urinary tract infections (1–10%)</td>
<td></td>
<td>– Check VZV IgG, if positive, consider Shingrix vaccination</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Herpes zoster infection (5–10%)</td>
<td></td>
<td>– Specific precautions in patients with increased risk for pulmonary embolism especially tofacitinib 10 mg bid</td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Abdominal discomfort, diarrhea, nausea (&lt;10%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Hypertension (&lt;10%), hyperlipidemia (&lt;1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>– Skin rash (&lt;10%), arthralgia (&lt;10%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Less systemic side effects due to high first-pass effect in the liver.

*Screening for active or latent tuberculosis including chest X-ray, Hepatitis B (HBs ag; anti-HBc ab), HIV serology, blood count, liver function; vaccination with live vaccines prior to initiation if indicated.

IBD, inflammatory bowel disease; 5-ASA, 5-aminosalicylates; TPMT, thiopurine methyltransferase; PML, progressive multifocal leukoencephalopathy; PRES, posterior reversible encephalopathy syndrome.
tantly with nonsteroidal anti-inflammatory drugs. This suggests that screening for risk factors for upper gastrointestinal bleeding should be routinely done and subsequent prophylactic PPI treatment installed [48]. Due to the high first-pass metabolism in the liver, budesonide or modified release formulations of budesonide have fewer systemic effects compared with prednisone and should be considered in mildly-to-moderately active disease in elderly IBD patients [49–51]. However, it has to be considered that side effects of topical steroids may be more frequent in the elderly patients.

**Immunosuppressive Drugs: Thiopurines, Methotrexate, Cyclosporine**

Thiopurines are purine antimetabolites that inhibit cell proliferation especially of lymphatic cells and are effective to maintain remission in CD and UC [38, 52]. No differences in efficacy have been noted with the use of thiopurines in the elderly [53]. However, the use of thiopurines in the elderly needs very careful consideration and monitoring due to potential drug interactions, increased risk of lymphoma, non-melanoma skin cancer, and infection [54]. Dose-dependent adverse events include nausea, vomiting, and dyspepsia and occurrence of leucopenia (in severe cases agranulocytosis) and elevation of transaminases; therefore, regular monitoring with complete blood count and liver function tests is required [55]. Determining the thiopurine methyltransferase activity may reduce the time to therapeutic drug levels and can help to identify patients at risk for myelosuppression and to prevent toxicity [55]. Allopurinol may enhance the myelosuppressive effects of thiopurines by blocking thiopurine methyltransferase activity. Blocking of this enzymatic activity with allopurinol with concomitant reduction of azathioprine (to 25–33% of normal weight based dose) is used in some patients with increased methylated 6-MMP levels ("hypermethylators") to enhance therapeutic efficacy. Dose-independent adverse event pancreatitis, flu like symptoms, and occurrence of rash can be observed in a minority of patients treated with thiopurines. The risk of lymphoma in IBD patients treated with azathioprine and 6-MMP was found increased especially in the elderly population [54, 56]. The CESAME cohort indicated that the risk significantly increases above the age of 65 [57]. There does not seem to exist a significant gender difference concerning the distribution of lymphoma except for the hepatosplenic T-cell lymphoma cases which were seen predominantly in younger men and not so relevant in the elderly population [58]. A recent study associated increasing age, especially in older men, with an increased risk of urinary tract cancers in patients with IBD receiving thiopurines [59]. In addition, patients on immunosuppressive medications have a substantially elevated risk of non-melanoma skin cancer [60]. IBD patients using thiopurines seem to have a moderately increased risk for non-melanoma skin cancer which is proportional to therapy duration and which decreases or returns to baseline risk after discontinuing therapy [61]. Younger patients with IBD using thiopurines seem to be at greater risk of developing non-melanoma skin cancer, which suggests early implementation of skin cancer screening recommendations and strict application of sun protection. In summary, there are ongoing discussions whether use of thiopurines in the elderly population is safe. In general, it is recommended to perform a very careful risk/benefit analysis given the increased cancer risk in the elderly population and thiopurines should be used with caution in this age group.

The use of methotrexate monotherapy in patients with IBD is of controversial discussion. Methotrexate has not been studied exclusively in elderly IBD patients, but retrospective cohort data indicate limited use in the elderly with similar outcomes compared to young patients [62]. In the rheumatology literature in older patients with rheumatoid arthritis (RA), similar responsiveness of methotrexate to that in younger patients was observed [63]. For patients with CD induction and maintenance of remission/clinical response with 10–25 mg methotrexate subcutaneous weekly was shown [64, 65]. The effect seems to be more pronounced in combination with anti-TNF therapy [66]. For patients with UC methotrexate was not found to be better than placebo in the induction, maintenance of remission, or preventing relapses of UC in patients who achieved steroid-free response [67, 68]. Attention should be given to symptoms of general malaise, gastrointestinal complaints, and asymptomatic increase of liver enzymes [62, 69]. Use of folic acid supplementation is mandatory in patients treated with methotrexate.

Cyclosporine is used for rescue therapy in severe UC patients. It is not recommended in elderly IBD patients given the risk profile for comorbidities such as hypertension and renal disease in this patient group [54, 70]. If cyclosporine is used, monitoring of the renal function should be assured.

**Biologics: TNFα Blockers, Anti-Integrins, and Anti IL-12/23**

Anti-TNF agents are used in moderate to severe CD and UC and are effective in inducing clinical and endoscopic remission, decreasing rates of hospitalization and
surgery. Although some data suggest a lower rate of short-term clinical response in elderly IBD patients to anti-TNFs there is no evidence that the efficacy of medical treatment in elderly IBD patients differs from that in younger adult patients [54, 71, 72]. In patients >65 years similar clinical remission rates of 59% in UC and 65% in CD after approximately 2 years of treatment on infliximab or adalimumab compared to younger patients was observed [73]. Long-term clinical response to anti-TNF agents seems to be similar between those initiating the drug before and after age 65 [71]. But patients older than age 60 at the time of initiation of anti-TNF therapy are at higher risk for discontinuation of therapy probably due to side effects such as increased vulnerability to infectious complications [74]. This goes in line with the finding that older corticosteroid-responsive patients were less likely to be treated with an anti-TNF than younger patients [72]. There are no specific data addressing the effectiveness of combination therapy, particularly anti TNFα treatment in combination with thiopurines in the elderly.

The most prominent adverse events due to anti TNFα therapy include infusion reactions, abdominal discomfort, infections (including bacterial, viral, fungal, and opportunistic infections) as well as rare occurrence of autoimmune, dermatological disorders, cardiac, and neurological conditions [75]. Cottone et al. [73] reported a 12% risk of serious infection in the elderly on anti-TNF agents, including pneumonia and sepsis. The increased use of TNFα in clinical practice raised concerns about a possible association with cancer. Data from registries regarding patients with RA showed that the overall incidence of cancer is similar to that observed in the general population [76, 77]. However, anti-TNFα treatment in combination with immunomodulators is associated with an increased risk of developing non-Hodgkin lymphoma in adult CD patients [78, 79]. As main risk factors for developing lymphoproliferative disorder older age, male sex, and longer duration of IBD were identified [57, 80]. Also, anti-TNF therapy has been associated in IBD patients with an increased risk of melanoma (OR 1.88; 95% CI 1.08–3.29), which was not confirmed in a large nested Canadian case-control study [81, 82]. The risk to develop recurrent malignancy on TNF-α inhibitor therapy in patients with previous malignancies cannot be definitively answered as studies have shown contradictory findings [83]. In the British biologics register for RA patients, treatment with TNFα inhibitor seems not to increase recurrent malignancy as the recurrent malignant incidence was not higher than the control group of RA patients with prior malignancy not treated with biologics [84].

In summary, anti-TNF-α agents are contraindicated in patients with cardiac insufficiency and must be used with caution in patients with chronic liver disease, neurological pathology, or history of malignancy, especially lymphoma in patients on combination with immunomodulators [85].

Newer biological therapies include the anti-integrin blocker vedolizumab and the monoclonal antibody ustekinumab blocking the IL-12/23 axis. The gut-specific integrin blocker vedolizumab has been shown to effectively induce remission and to maintain remission in patients moderate to severe CD and UC [86, 87]. In a small study, the efficacy and safety of VDZ in elderly patients (>60 years old) with UC and CD were shown with clinical remission rate of 41% at week 52 [88]. In a pooled post hoc analysis, vedolizumab shows a favorable safety profile with low incidence rates of serious infections, infusion-related reactions, and malignancies over an extended treatment period. No increased risk of any infection or serious infection was associated with vedolizumab exposure [89]. Risk factors associated with serious infection for vedolizumab treated patients with CD were younger age, concurrent corticosteroids, and opiate use. No cases of progressive multifocal leukoencephalopathy related to the JC virus reactivation were reported as it was a concern during the use of its nonselective anti-integrin predecessor natalizumab.

Similarly, ustekinumab that effectively induces and maintains remission in patients with moderate to severe CD seems to offer a favorable infectious safety profile. Randomized clinical trials demonstrated so far no increased infection frequency compared to placebo [90].

Small Molecules: Tofacitinib

Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to be more effective as induction and maintenance therapy than placebo in moderately to severely active UC [91]. In a safety analysis of patients with moderate to severe UC treated with tofacitinib, additional serious infectious risk was observed, especially a dose relationship with herpes zoster infection [92]. Experience from patients with RA receiving tofacitinib demonstrates that in most cases (93%) herpes zoster was classified as nonserious, and the majority of patients (94%) had involvement of only 1 dermatome [93]. Shingrix a new herpes zoster subunit vaccine containing recombinant varicella-zoster virus glycoprotein E was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older [94]. Herpes zoster-related complications in immunocompetent adults were found...
to be reduced by approximately 90% in adult ≥70 years [95]. Although Shingrix has not yet been tested in immuno-suppressed individuals this inactivated recombinant herpes zoster vaccination may become a recommended vaccine before starting tofacitinib.

Surgery
The indications for surgery are not different between elderly and younger adult patients in both CD and UC. Elderly UC patients were less likely to undergo surgery compared to younger UC patients and have lower rates of total colectomy as well as segmental colectomy [96–99]. In CD patients, the necessity for surgery appears to be lower with a higher age at the onset of disease [100, 101]. In severe UC, early surgery has been recommended for elderly patients in order to reduce complications [102]. In UC patients requiring pouch surgery, the surgical approach is not different from younger adult patients and a favorable functional outcome is observed when the patient had a good anal sphincter function documented pre-operatively [103, 104]. However, in case of decreased anal sphincter function, the option of permanent ileostomy instead of ileal anal pouch should be discussed in elderly patients [54]. Overall, elderly IBD patients were found to have a longer postoperative stay and a higher in-hospital mortality rate [105]. Age is independently associated with postoperative morbidity and mortality with preoperative transfusion, emergency operation, and weight loss predicting morbidity for those 80 years of age and older [106]. The rate of major postoperative complications and death among elderly patients has improved in the last decades, which are probably due to availability of more effective IBD medical management, higher emphasis on improving preoperative nutritional status, early mobilization, and/or an increased tendency to perform surgery earlier in the course of disease [107, 108].

General Considerations and Recommendations for the Management of Elderly Patients (Table 2)

Nutrition
Malnutrition is being observed in IBD due to any combination of inadequate dietary intake associated with feeling unwell, altered nutritional requirements, and/or impairment of nutrient absorption [109]. Malnutrition has been reported in patients with IBD with a prevalence rate of 14% for patients with CD and 5.7% with UC and with clearly increased frequencies for hospitalized patients [110, 111]. Decreased food intake, nutrient malabsorption, increased intestinal loss, increased energy expenditure, as well as drug interactions may contribute to protein-calorie malnutrition and can be in consequence a considerable risk factor for infectious and other disease-specific complications. Localization, extension of inflammation, disease activity, as well as resection of bowel are some crucial risk factors for deficiencies of macronutrients and of specific micronutrients such as trace elements as well as vitamins and should be monitored when suspected and supplemented if deficiency is observed.

Osteoporosis
Risk of osteoporosis and osteoporotic fractures is increased in all IBD patients. Besides age-related bone loss elderly IBD patients are at increased risk of osteoporosis and related fractures due to malnutrition, vitamin D deficiency, corticosteroid treatment, and reduced physical activity [47]. Preventive measures such as supplementation with vitamin D/calcium, adequate treatment of the underlying disease, and monitoring with osteodensitometry are required.

Infections
Due to the modification of the immune system in IBD patients, infectious complications – both common and opportunistic – have to be considered during therapy with immunomodulators or biologics. Compared to the non-IBD population, IBD patients are at increased risk of infectious complications including influenza, pneumonia, herpes zoster, Clostridium difficile infection, CMV colitis, and others [112–114]. Opportunistic infections are associated with anti-TNFs, and the risk of opportunistic infection increases with age with patients over 50 years carrying a 3 times increased risk [115]. Severe infections that require admission to the intensive care unit, multiple organ dysfunction, or which fulfill systemic inflammatory response criteria are associated with increased morbidity and mortality. In patients with viral illness experiencing either a severe primary infection or reactivation, biological therapy should be interrupted until appropriate therapy is instituted and clinical improvement is observed. With mild infections biological treatment can be continued [116]. Therefore, assessing an individual patient’s risk of therapeutic complications is the first step to improving safety with biologic agents. Treatment guidelines recommend that patients be tested for tuberculosis, hepatitis B, HIV and when appropriate, vaccinations should be given before initiation of biologicals or immunosuppressive treatment [85].
Vaccinations

Immunosenescence makes the elderly more susceptible to infections and in consequence complications of infections. The vaccination guidelines for elderly IBD patients are similar to those for patients without CD or UC. When possible, patients with IBD should receive age-appropriate vaccinations before initiation of immunosuppression [117]. It has to be considered that immunosuppressed patients >60 years appear to respond less well to vaccinations. In general, inactivated vaccinations are safe for administration in immunosuppressed individuals. Recommendations for vaccinations in the elderly are presented in Table 3. Specifically, older patients should be given the influenza vaccine annually and the pneumococcal vaccine with a booster revaccination after 5 years [118].

As mentioned before, Shingrix a new herpes zoster subunit vaccine may become a recommended vaccine before starting tofacitinib. However, patients prescribed biologics and other immunosuppressants should avoid live vaccines, although following the guidelines of the Infectious Disease Society of America live vaccines in those on low dose immunosuppression (prednisone ≤20 mg/day, azathioprine ≤3.0 mg/kg/day, MMP ≤1.5 mg/kg/day, methotrexate ≤0.4 mg/kg/week) may be considered [119].

Thrombotic Complications

Spontaneous reporting (pharmacovigilance database VigiBase) of cases of pulmonary embolism and thromboembolism in connection with infliximab should increase the awareness of physicians for such events/complica-
tions, especially in IBD patients treated with newer drugs. In general, the thrombotic risk in elderly patients is probably underestimated, but thrombotic complications in case of hospitalization represent an increased risk in IBD patients and need prevention. Antithrombotic prophylaxis should therefore be considered in all hospitalized elderly patients with IBD. Treatment of venous thromboembolism in IBD should follow established antithrombotic therapy options taking into account a potentially increased risk of bleeding [54, 120].

Cancer Screening
Thiopurine therapy seems to moderately increase the risk for nonmelanoma skin cancer and the risk of lymphoma in patients with IBD [54, 56, 121]. Both azathioprine and 6-MMP are known photosensitizers that reduce the minimal erythema dose for UV-A radiation and also play a role in generation of reactive oxygen species [122, 123]. The increased risk for nonmelanoma skin cancer does not seem to be daily dose-dependent but some studies show a duration-dependent (cumulative dose) trend for increasing risk [124]. Therefore, the importance of sun protective measures and benefits of regular skin cancer screening should be considered.

In a population-based cohort of nearly 30,000 women with IBD reported increased risk for cervical dysplasia in women with IBD and increased risk of cervical cancer [125]. In a retrospective analysis of women under 65 years of age with IBD, 15% had abnormal Pap smears compared to 5% among normal patient populations [126]. Therefore, women with IBD on immunosuppressive therapy should undergo annual cervical cancer screening [117].

Table 3. Recommended vaccinations for elderly patients with IBD (adapted from [117])

<table>
<thead>
<tr>
<th>Vaccination</th>
<th>Guidelines for administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inactivated vaccines</strong></td>
<td></td>
</tr>
<tr>
<td>Tdap</td>
<td>A single dose of Tdap recommended at age 11 through 64 years; single dose ofTd (tetanus/diphtheria) every 10 years</td>
</tr>
<tr>
<td>Hepatitis A</td>
<td>Titer check HAV ab; if negative 2 doses at 0 and 6 months</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>Titer check HBs ab; if negative 3 doses at 1, 1–2, and 4–6 months; optional titer check 1 month after the last dose</td>
</tr>
<tr>
<td>Streptococcus pneumoniae&lt;sup&gt;a&lt;/sup&gt; (PCV13 and PPSV 23)</td>
<td>Patients at age 65 years or older if at least 5 years have elapsed since their previous PPSV23 dose</td>
</tr>
<tr>
<td>Neisseria meningitidis</td>
<td>2 or 3 doses depending on vaccine in high-risk situations (e.g., splenectomy, travel to endemic areas, military, employee day/preschool care)</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>2 doses Shingrix (2–6 months apart)</td>
</tr>
<tr>
<td>Influenza</td>
<td>Annual immunization with inactivated tri- or quadrivalent influenza vaccine for patients 65 and older; live-attenuated intranasal influenza vaccine contraindicated in immunosuppressed patients</td>
</tr>
<tr>
<td>Tick borne encephalitis</td>
<td>3 doses (0, 2–4 weeks and 6–12 months; booster every 10 years, recommended in endemic areas with potential exposition to ticks</td>
</tr>
</tbody>
</table>
Elderly IBD Patient

Colorectal Cancer Screening and Tumor Risk in the Elderly

Colorectal cancer (CRC) screening is recommended in all individuals beyond age 50 and for IBD patients, starting of screening colonoscopy is advised 8 years after onset of IBD symptoms [127]. However, several publications suggest that onset of screening in elderly IBD patients should be initiated earlier. In a population-based study, age at diagnosis was a significant risk factor for early-onset CRC cases with 35% of older patients with both IBD and CRC developed the CRC within 8 years of the IBD diagnosis [128]. A large cohort study found a much shorter interval to diagnosis of flat dysplasia in elderly patients with UC [129]. Other factors that influence the frequency of colonoscopies for surveillance in IBD patients include family history of CRC, severe and extensive colitis, past dysplasia, or primary sclerosing cholangitis [127]. In the elderly, CRC screening should be balanced with disease severity, comorbidities, and life expectancy.

Conclusion

The medical management of elderly patients with IBD is challenging with respect to diagnosis, drug therapy, and surgical treatment. In recent years, patients older than 65 were systematically excluded from clinical trials and therefore important information about therapy success, outcome, adverse events, and general epidemiological information is often extrapolated from younger IBD populations. It is questionable whether this is ethical. With our ageing population, it needs to be changed urgently to gain better evidence for the treatment of the elderly.

Acknowledgment

No funding was provided for this manuscript.

Disclosure Statement

The authors have no conflicts of interest to declare related to this manuscript.

Author Contributions

All authors conceptualized the extent of the manuscript. P.H. and G.R. drafted the initial manuscript. All authors critically reviewed and approved the final manuscript as submitted.

References

8 Niess JH, Kaymak T, Hruz P. [The Role of the Exposome in the Emergence of Chronic Inflammatory Bowel Diseases]. Ther Umsch. 2019 Jan;75(5):261–70.
9 Rogler G, Vavricka S. Exposome in IBD: recent insights in environmental factors that influence the onset and course of IBD. Inflamm Bowel Dis. 2015 Feb;21(2):400–8.


